NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GANX

Gain Therapeutics Inc

Jun 24 • 04:00PM ET

1.79

Dollar change +0.10
Percentage change 5.92	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX ALNY SRPT NBIX CRSP IONS BMRN FATE RARE TVRD

| Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	4.90%	Shs Outstand	28.75M	Perf Week	2.87%
Market Cap	53.60M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	0.00%	Shs Float	28.48M	Perf Month	-0.28%
Enterprise Value	45.14M	PEG	-	EPS next Q	-0.17	Inst Own	9.39%	Short Float	1.02%	Perf Quarter	-22.84%
Income	-20.93M	P/S	-	EPS this Y	28.96%	Inst Trans	41.70%	Short Ratio	1.05	Perf Half Y	16.23%
Sales	0.00M	P/B	8.90	EPS next Y	-12.01%	ROA	-159.74%	Short Interest	0.29M	Perf YTD	-17.13%
Book/sh	0.20	P/C	5.91	EPS next 5Y	12.30%	ROE	-290.21%	52W High	3.19 -43.89%	Perf Year	37.69%
Cash/sh	0.30	P/FCF	-	EPS past 3/5Y	13.25% -37.02%	ROIC	-341.68%	52W Low	0.89 101.12%	Perf 3Y	-45.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.88% 3.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	40.96%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.22	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	47.47	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.22	EPS Q/Q	29.29%	SMA20	-1.86%	Beta	0.11	Target Price	8.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	-4.08%	Rel Volume	0.66	Prev Close	1.69
Employees	25	LT Debt/Eq	0.06	Earnings	May 14 BMO	SMA200	-9.45%	Avg Volume	278.42K	Price	1.79
IPO	Mar 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.01% -100.00%	Trades		Volume	184,964	Change	5.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$12
Dec-06-24	Initiated	ROTH MKM	Buy	$7
Aug-14-24	Resumed	Oppenheimer	Outperform	$8
Apr-12-21	Initiated	Oppenheimer	Outperform	$30
Apr-12-21	Initiated	BTIG Research	Buy	$30

Jun-10-25 08:00AM	Gain Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-25 08:45AM	Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting (GlobeNewswire)
May-14-25 07:30AM	Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-12-25 07:30AM	Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders (GlobeNewswire)
May-01-25 07:30AM	Gain Therapeutics to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +6.34%
07:45AM	Loading…
Apr-30-25 07:45AM	Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders (GlobeNewswire) +9.04%
Apr-11-25 02:59PM	Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey) +6.52%
Apr-10-25 07:00AM	Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update (GlobeNewswire)
Mar-28-25 08:30AM	Gain Therapeutics Announces Poster Presentation at AD/PD 2025 (GlobeNewswire) -8.70%
Mar-27-25 07:00AM	Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update (GlobeNewswire)
Mar-14-25 07:45AM	Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease (GlobeNewswire)
Mar-06-25 07:55AM	Gain Therapeutics Announces Oral Presentation at AD/PD 2025 (GlobeNewswire)
Feb-06-25 08:45AM	Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update (GlobeNewswire) +8.20%
Feb-05-25 08:30AM	Gain Therapeutics To Participate in Upcoming Investor Conferences (GlobeNewswire) +10.41%
Jan-16-25 12:00PM	All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy (Zacks) +10.75%
08:00AM	Loading…
Jan-08-25 08:00AM	Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 (GlobeNewswire) +7.49%
Jan-07-25 07:00AM	Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director (GlobeNewswire) -6.97%
Dec-25-24 07:40AM	Gain Therapeutics GT-02287 study to deliver positive findings, says Roth MKM (TipRanks)
Dec-23-24 07:30AM	Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease (GlobeNewswire)
Dec-11-24 08:30AM	Gain Therapeutics To Present At Biotech Showcase 2025 (GlobeNewswire)
Nov-14-24 04:05PM	Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire) -14.04% +5.73%
Oct-23-24 08:00AM	Gain Therapeutics Presents Data at 36 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 (GlobeNewswire)
Oct-15-24 07:00AM	Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference (GlobeNewswire)
Oct-07-24 07:00AM	Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 (GlobeNewswire) +17.31%
Oct-03-24 07:00AM	Gain Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-30-24 07:00AM	Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers (GlobeNewswire) -10.55%
Sep-26-24 07:00AM	Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease (GlobeNewswire)
Sep-19-24 07:00AM	Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 (GlobeNewswire)
Sep-03-24 07:00AM	Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
04:52AM	Loading…
Aug-30-24 04:52AM	Gain Therapeutics reports positive data from Phase I Parkinsons treatment trial (Clinical Trials Arena)
Aug-29-24 07:30AM	Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease (GlobeNewswire) -20.15%
Aug-08-24 07:30AM	Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire)
Aug-01-24 08:00AM	Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace)
Jul-09-24 07:00AM	Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease (GlobeNewswire) +5.36%
Jul-08-24 12:00PM	Gain Therapeutics (GANX) Upgraded to Buy: Here's Why (Zacks) -6.67%
Jun-28-24 04:39PM	Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 (GlobeNewswire) -12.50%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 04:08PM	Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO (GlobeNewswire)
08:35AM	Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease (GlobeNewswire)
Jun-25-24 07:00AM	Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-14-24 08:37AM	Why Is Gain Therapeutics (GANX) Stock Down 25% Today? (InvestorPlace) -34.39%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 09:00PM	Gain Therapeutics Announces Pricing of $11.0 Million Public Offering (GlobeNewswire) -10.43%
04:44PM	Gain Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-30-24 07:00AM	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 (GlobeNewswire) +5.46%
May-14-24 01:54PM	GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-03-24 10:00AM	Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-24-24 09:25AM	Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire) -5.90%
Apr-17-24 09:55AM	Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher (Zacks)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
09:35AM	Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) (Zacks)
Apr-08-24 09:25AM	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer (GlobeNewswire)
Apr-02-24 05:40PM	Insiders Are Buying These 5 Penny Stocks (Insider Monkey)
Apr-01-24 07:01PM	Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX) (GuruFocus.com)
09:25AM	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Mar-26-24 01:53PM	GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:00AM	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update (GlobeNewswire)
Mar-15-24 02:30PM	Gain Therapeutics to Present at Public Ventures Discovery Day (GlobeNewswire)
Mar-05-24 09:45AM	EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease (Benzinga)
08:00AM	Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease (GlobeNewswire)
Feb-27-24 02:00PM	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire)
Feb-14-24 12:29PM	Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight (GlobeNewswire)
Feb-06-24 09:56AM	UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease (GlobeNewswire)
08:00AM	Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease (GlobeNewswire)
Jan-31-24 08:00AM	Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update (GlobeNewswire)
Jan-24-24 12:00PM	Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-02-24 08:00AM	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium 2024 (GlobeNewswire) +11.03%
Dec-14-23 09:55AM	Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now (Zacks) -5.22%
Dec-04-23 08:00AM	Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research (GlobeNewswire) +6.82%
Dec-01-23 08:00AM	Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model (GlobeNewswire)
Nov-29-23 08:00AM	Gain Therapeutics to Participate in AI Driven Drug Discovery Summit (GlobeNewswire)
Nov-24-23 01:01PM	Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Nov-22-23 11:58AM	Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock (Zacks)
Nov-21-23 08:54AM	Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants (GlobeNewswire) -23.90%
Nov-20-23 04:03PM	Gain Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-14-23 07:00AM	Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-04-23 08:45AM	Why Is Gain Therapeutics (GANX) Stock Moving Today? (InvestorPlace) -6.62%
07:00AM	Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire)
Sep-25-23 04:05PM	Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-20-23 04:05PM	Gain Therapeutics to Present at the Cambridge Healthtech Institutes 2nd Annual Neurodegeneration Targets Conference (GlobeNewswire) -5.00%
Sep-12-23 09:25AM	Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia (GlobeNewswire)
Aug-29-23 08:57AM	Gain Therapeutics Achieves Remarkable Breakthrough in Parkinsons Disease Research (News Direct)
Aug-28-23 07:00AM	Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinsons Disease Model (GlobeNewswire)
Aug-10-23 08:25AM	Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.33%
07:00AM	Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-07-23 07:00AM	Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinsons Disease and Movement Disorders® (GlobeNewswire)
Jul-31-23 08:00AM	Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-01-23 08:00AM	Gain Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-23 08:09AM	Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 09:15AM	Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-08-23 10:00AM	Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for (Zacks)
May-03-23 09:15AM	Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinsons Disease (GlobeNewswire)
Apr-12-23 04:30PM	Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer (GlobeNewswire)
Mar-29-23 08:52AM	Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting (GlobeNewswire)
Mar-23-23 04:05PM	Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Mar-22-23 08:30AM	Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders (GlobeNewswire)

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mack Gene	CFO and Interim CEO	Aug 09 '24	Buy	1.01	14,400	14,544	14,400	Aug 12 05:23 PM
Islam Khalid	Executive Chairman	Aug 09 '24	Buy	1.00	50,000	49,940	50,000	Aug 12 05:23 PM
RICHMAN ERIC I	Director	Jul 01 '24	Buy	1.22	17,000	20,670	289,629	Jul 01 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GANX

Gain Therapeutics Inc

Upgrade your FINVIZ experience